FDA Incentivizes Domestic Generic Drug Production to Bolster National Security & Supply Chain Resilience
Table of Contents
The Food and Drug Administration (FDA) announced a new pilot program Friday designed to incentivize the domestic manufacturing of generic drugs, addressing a critical imbalance in the U.S. pharmaceutical supply chain and aiming to reduce reliance on foreign production. The initiative seeks to expedite the regulatory review process for generic medications produced entirely within U.S. borders, from ingredient sourcing to finished product.
The move comes as a response to the fact that over half of all pharmaceuticals distributed in the U.S. are manufactured overseas, according to the FDA. Even drugs assembled domestically often rely on active pharmaceutical ingredients (APIs) sourced from abroad – a situation that raises concerns about national security and supply chain vulnerabilities. Currently, only 9% of API manufacturers are located in the U.S., compared to 22% in China and 44% in India.
Reshoring Pharmaceuticals: A Multi-Pronged Approach
The new pilot program requires participating drugmakers to source all ingredients and complete the manufacturing process within the United States. This aligns with broader efforts by the previous administration to reshore pharmaceutical manufacturing and strengthen domestic production capabilities. To qualify for expedited review, companies must provide documentation verifying adherence to these requirements, including proof of U.S.-based bioequivalence testing – a standard requirement for generic drug approval demonstrating comparable effectiveness to existing branded medications.
“Overreliance on foreign drug manufacturing and testing creates risks both to national security and patient access, and undermines investments in U.S. research, manufacturing and production,” stated George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research, in the agency’s announcement. He further emphasized that foreign inspections are more time-consuming and costly for taxpayers than domestic oversight.
Branded Drugs Already Receiving Priority Review
While the FDA has not yet quantified the speedup expected for generic drug reviews under the new pilot program, domestic production is already a key factor in a separate initiative focused on branded pharmaceuticals. Launched in June, this program offers a shorter regulatory review – as short as two months with a Commissioner’s National Priority Review Voucher – for drugs addressing national health crises or bolstering domestic production as a matter of national security.
Tariffs and Executive Orders Drive Domestic Investment
The push for domestic pharmaceutical production has been fueled, in part, by the threat of potential pharmaceutical tariffs on imported drugs. In late September, the former president indicated that tariffs would be imposed on branded drugs unless manufacturers initiated construction of U.S. manufacturing plants. While the announcement did not extend to generic drugs, it signaled a clear preference for domestic production.
Further bolstering these efforts, a series of executive orders have been issued to streamline the approval process for new domestic manufacturing facilities. In May, an order directed the FDA to evaluate existing regulations to expedite permitting. The FDA subsequently introduced “PreCheck” in August, a program offering increased communication and streamlined review of chemistry, manufacturing, and controls applications for new facilities. A public meeting to discuss the PreCheck program was held last week.
Stockpiling Critical APIs for Supply Chain Security
Another executive order, issued in August, directs the Department of Health and Human Services to identify critical medicines and stockpile their APIs. This initiative aims to insulate the U.S. from the concentration of API production in foreign countries and further incentivize domestic API manufacturing.
The FDA’s multifaceted approach signals a significant shift towards prioritizing domestic pharmaceutical production, driven by concerns over national security, supply chain resilience, and the long-term health of the U.S. pharmaceutical and research and development infrastructure.
